Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma
Preclinical in vitro studies of drug candidates for anticancer therapy are generally conducted on well-established 2D cell models. Unfortunately, these models are unable to mimic the properties of in vivo tumors. However, in vitro 3D models (spheroids) have been proven to be superior in reflecting t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/6/894 |
| _version_ | 1797529887618105344 |
|---|---|
| author | Friederike Hartwig Monika Köll-Weber Regine Süss |
| author_facet | Friederike Hartwig Monika Köll-Weber Regine Süss |
| author_sort | Friederike Hartwig |
| collection | DOAJ |
| description | Preclinical in vitro studies of drug candidates for anticancer therapy are generally conducted on well-established 2D cell models. Unfortunately, these models are unable to mimic the properties of in vivo tumors. However, in vitro 3D models (spheroids) have been proven to be superior in reflecting the tumor microenvironment. Diethyldithiocarbamate (DDC<sup>−</sup>) is the active metabolite of Disulfiram, an approved drug for alcoholism and repurposed for cancer treatment. DDC<sup>−</sup> binds copper in a molar ratio of 2:1 resulting in a water-insoluble Cu(DDC)<sub>2</sub> complex exhibiting anticancer activities. Delivery of the Cu(DDC)<sub>2</sub> complex using nanoparticulate carriers provides decisive advantages for a parental application. In this study, an injectable liposomal Cu(DDC)<sub>2</sub> formulation was developed and the toxicity was compared with a 2D neuroblastoma and a 3D neuroblastoma cell model. Our results indicate that Cu(DDC)<sub>2</sub> liposomes complied with the size requirements of nanoparticles for intravenous injection and demonstrated high drug to lipid ratios as well as colloidal stability upon storage. Furthermore, an efficient cytotoxic effect on neuroblastoma 2D cell cultures and a very promising and even more pronounced effect on 3D cell cultures in terms of neuroblastoma monoculture and neuroblastoma co-culture with primary cell lines was proven, highly encouraging the use of Cu(DDC)<sub>2</sub> liposomes for anticancer therapy. |
| first_indexed | 2024-03-10T10:20:16Z |
| format | Article |
| id | doaj.art-315293cf410547d2b4b94aac215d9258 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T10:20:16Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-315293cf410547d2b4b94aac215d92582023-11-22T00:27:06ZengMDPI AGPharmaceutics1999-49232021-06-0113689410.3390/pharmaceutics13060894Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of NeuroblastomaFriederike Hartwig0Monika Köll-Weber1Regine Süss2Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, Sonnenstr. 5, 79104 Freiburg, GermanyDepartment of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, Sonnenstr. 5, 79104 Freiburg, GermanyDepartment of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, Sonnenstr. 5, 79104 Freiburg, GermanyPreclinical in vitro studies of drug candidates for anticancer therapy are generally conducted on well-established 2D cell models. Unfortunately, these models are unable to mimic the properties of in vivo tumors. However, in vitro 3D models (spheroids) have been proven to be superior in reflecting the tumor microenvironment. Diethyldithiocarbamate (DDC<sup>−</sup>) is the active metabolite of Disulfiram, an approved drug for alcoholism and repurposed for cancer treatment. DDC<sup>−</sup> binds copper in a molar ratio of 2:1 resulting in a water-insoluble Cu(DDC)<sub>2</sub> complex exhibiting anticancer activities. Delivery of the Cu(DDC)<sub>2</sub> complex using nanoparticulate carriers provides decisive advantages for a parental application. In this study, an injectable liposomal Cu(DDC)<sub>2</sub> formulation was developed and the toxicity was compared with a 2D neuroblastoma and a 3D neuroblastoma cell model. Our results indicate that Cu(DDC)<sub>2</sub> liposomes complied with the size requirements of nanoparticles for intravenous injection and demonstrated high drug to lipid ratios as well as colloidal stability upon storage. Furthermore, an efficient cytotoxic effect on neuroblastoma 2D cell cultures and a very promising and even more pronounced effect on 3D cell cultures in terms of neuroblastoma monoculture and neuroblastoma co-culture with primary cell lines was proven, highly encouraging the use of Cu(DDC)<sub>2</sub> liposomes for anticancer therapy.https://www.mdpi.com/1999-4923/13/6/894DisulfiramCu(DDC)<sub>2</sub>liposomesdrug deliverystorage stabilityneuroblastoma |
| spellingShingle | Friederike Hartwig Monika Köll-Weber Regine Süss Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma Pharmaceutics Disulfiram Cu(DDC)<sub>2</sub> liposomes drug delivery storage stability neuroblastoma |
| title | Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma |
| title_full | Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma |
| title_fullStr | Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma |
| title_full_unstemmed | Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma |
| title_short | Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)<sub>2</sub> Containing Liposomes for the Treatment of Neuroblastoma |
| title_sort | preclinical in vitro studies with 3d spheroids to evaluate cu ddc sub 2 sub containing liposomes for the treatment of neuroblastoma |
| topic | Disulfiram Cu(DDC)<sub>2</sub> liposomes drug delivery storage stability neuroblastoma |
| url | https://www.mdpi.com/1999-4923/13/6/894 |
| work_keys_str_mv | AT friederikehartwig preclinicalinvitrostudieswith3dspheroidstoevaluatecuddcsub2subcontainingliposomesforthetreatmentofneuroblastoma AT monikakollweber preclinicalinvitrostudieswith3dspheroidstoevaluatecuddcsub2subcontainingliposomesforthetreatmentofneuroblastoma AT reginesuss preclinicalinvitrostudieswith3dspheroidstoevaluatecuddcsub2subcontainingliposomesforthetreatmentofneuroblastoma |